Litcius/Paper detail

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen, Charles Gleason, Sarita Agte, Komal Srivastava, Katherine F. Beach, Adolfo Aleman, Katerina Kappes, Radhika Banu, Maria C. Bermúdez‐González, Rachel Chernet, Emily D. Ferreri, Daniel Floda, Adolfo Firpo‐Betancourt, Giulio Kleiner, Kayla T. Russo, Ashley-Beathrese T. Salimbangon, Miti Saksena, Amber A. Shin, Julia C. Matthews, Wanni A. Mendez, Levy A. Sominsky, Lubbertus C. F. Mulder, Rao Mendu, Tarek H. Mouhieddine, Bo Wang, Ajai Chari, Carlos Cordon‐Cardo, Florian Krammer, Sundar Jagannath, Viviana Simon, Ania Wajnberg, Samir Parekh

2021Cancer Cell216 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMultiple myelomaAntibodyImmunologyVaccinationMedicine2019-20 coronavirus outbreakImmunizationImmunityPandemicImmune systemBiologyOutbreakInternal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesImmunotherapy and Immune Responses
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma | Litcius